Prosecution Insights
Last updated: November 10, 2026
Application No. 18/253,693

FUNCTIONALIZED POLYGLYCINE-POLY(ALKYLENIMINE) COPOLYMERS, THEIR PREPARATION AND USE FOR PREPARING ACTIVE INGREDIENT FORMULATIONS AND SPECIAL-EFFECT SUBSTANCE FORMULATIONS

Final Rejection §103
Filed
May 19, 2023
Priority
Nov 21, 2020 — DE 102020007116.3 +2 more
Examiner
MCCULLEY, MEGAN CASSANDRA
Art Unit
1767
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Friedrich-Schiller-Universität Jena
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
442 granted / 754 resolved
-6.4% vs TC avg
Strong +16% interview lift
Without
With
+16.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
25 currently pending
Career history
793
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
54.3%
+14.3% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
25.6%
-14.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 754 resolved cases

Office Action

§103
DETAILED ACTION Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5, 12 and 14-16 are rejected under 35 U.S.C. 103 as being unpatentable over Hedrick et al. (US 2016/0213707). Regarding claims 1, 2, and 3: Hedrick et al. teaches a polyamine having an N-acylated ethylenimine unit having the structure PNG media_image1.png 130 206 media_image1.png Greyscale (para. 83), which reads on claimed formula (I) where R3 and R4 are hydrogen in an amount of 1-70% (para. 73). The *---C(=O)K’ group can be PNG media_image2.png 86 156 media_image2.png Greyscale (para. 95), which is the embodiment where R1 is -CO-R2 and R2 is –(CnH2n-O)o-(CpH2p-O)q-R6, where o is zero, p is 2, q is 1 and R6 is hydrogen. Hedrick et al. also teaches the structural unit of claimed formula (II)/disclosed formula (5) (para. 98) PNG media_image3.png 82 206 media_image3.png Greyscale which is claimed formula (II) where R7 is hydrogen in an amount of 1-50 units out of 100-400 total units (para. 103), which is 12.5-50 mol %, which overlaps the claimed range. Hedrick et al. also teaches that a structure of claimed formula (III)/disclosed formula (3b) is optional when an alternative structure such as structure (3a) is present (para. 84-90) and can therefore be 0 mol%. In the case where the claimed ranges overlap or lie inside ranges disclosed by the prior art, a prima facie case of obviousness exists (MPEP 2144.05 I). Before the effective filing date of the claimed invention a person having ordinary skill in the art would have found it obvious to use the overlapping amount of monomer units in the copolymer of Hedrick et al. and would have been motivated to do so since Hedrick et al. teaches these are acceptable amounts to achieve the disclosed invention. Regarding claims 4, 15, and 16: Hedrick et al. further teaches the unit PNG media_image4.png 130 218 media_image4.png Greyscale (para. 99), which reads on formula (I) where R1 is -CO-R2 and R2/R’ is methyl, ethyl, propyl or butyl. Regarding claim 5: Hedrick et al. teaches the case where R2 is alkyl and therefore the embodiment where R2 is –(CnH2n-O)o-(CpH2p-O)q-R6 is optional. Regarding claims 12 and 14: Hedrick et al. teaches the polyamines can be in the form of a powder containing pharmaceutical active ingredients (para. 144). Claim 13 is rejected under 35 U.S.C. 103 as being unpatentable over Hedrick et al. (US 2016/0213707) as applied to claim 12 set forth above and in view of Englert et al. “Enhancing the biocompatibility and biodegradability of linear poly(ethylene imine) through controlled oxidation.” Macromolecules (2015). Regarding claim 13: Hedrick et al. teaches the basic claimed particle as set forth above. Not disclosed is the size. However, Englert et al. teaches a similar polyamine having a size of less than 1 µm (fig. 6B). Hedrick et al. and Englert et al. are analogous art since they are both concerned with the same field of endeavor, namely poly(ethylene) imines. Before the effective filing date of the claimed invention a person having ordinary skill in the art would have found it obvious to use the size of Englert et al. for the particles of Hedrick et al. and would have been motivated to do so in order to make them more bioavailable to cells. Claims 13 and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Hedrick et al. (US 2016/0213707) as applied to claim 12 set forth above and in view of Lizio et al. (US 2017/0333361). Regarding claims 13 and 17: Hedrick et al. teaches the basic claimed particles as set forth above. Not disclosed is the size. However, Lizio et al. teaches a similar particle made of polyethylene imines having an active ingredient in a range of 10-300 nm (abstract). Hedrick et al. and Lizio et al. are analogous art since they are both concerned with the same field of endeavor, namely polyethylene imine particles with active ingredients. Before the effective filing date of the claimed invention a person having ordinary skill in the art would have found it obvious to make the particles of Hedrick et al. with the size of Lizio et al. and would have been motivated to do so since Lizio et al. discloses that this size can yield an almost transparent dispersion (examples). Response to Arguments Applicant's arguments filed August 18, 2026 have been fully considered but they are not persuasive. A) Applicant’s argument that Scheme 3 of Hedrick et al. no longer recites an embodiment that reads on the claims is not persuasive since the *---C(=O)K’ group can be PNG media_image2.png 86 156 media_image2.png Greyscale (para. 95), which is the embodiment where R1 is -CO-R2 and R2 is –(CnH2n-O)o-(CpH2p-O)q-R6, where o is zero, p is 2, q is 1 and R6 is hydrogen. B) Applicant’s argument that the modification of Hedrick et al. required to arrive at the claimed copolymer would change the principle of operation of Hedrick et al. is not persuasive. Hedrick et al. teaches each of the claimed limitations of claim 1 in overlapping ranges. C) Applicant’s argument that Hedrick et al. requires two mandatory elements, units of (3a) and a hydroxyl group bearing K’ group is not germane as the instant claims do not exclude either of these elements. D) Applicant’s argument that a person having ordinary skill in the art would have no motivation to combine Hedrick et al. and Englert since Englert produces polymers that lack mannose groups entirely is not persuasive. Hedrick et al. does not require mannose groups, paragraph 74 does not contain the word mannose, and mannose groups are one optional embodiment of the K’ groups. Other K’ groups can be present instead, such as the K’ groups highlighted in the rejection above (see para. 92 of Hedrick et al.). Therefore, a person having ordinary skill in the art would not discard Englert for not mentioning mannose groups. E) Applicant’s argument that the terminal disclaimer filed overcomes the double patenting rejection is not persuasive. The terminal disclaimer was not approved, as discussed below. However, the claims of application 18/253,649 were amended so that there is no longer overlapping scope between the instant application and the copending application. Terminal Disclaimer The terminal disclaimer filed on August 18, 2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of any patent granted on Application Number 18/253,649 has been reviewed and is NOT accepted. The terminal disclaimer does not comply with 37 CFR 1.321 because: This application was filed on or after September 16, 2012. The person who signed the terminal disclaimer is not the applicant, the patentee or an attorney or agent of record. See 37 CFR 1.321(a) and (b). Please file a power of attorney that gives power to the attorney who is signing the terminal disclaimer, along with another copy of the terminal disclaimer that is signed by the applicant. It should be noted that applicant is not required to pay another disclaimer fee as set forth in 37 CFR 1.20(d) when submitting a replacement or supplemental terminal disclaimer. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Megan McCulley whose telephone number is (571)270-3292. The examiner can normally be reached Monday - Friday 9-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark Eashoo can be reached at 571-272-1197. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGAN MCCULLEY/Primary Examiner, Art Unit 1767
Read full office action

Prosecution Timeline

May 19, 2023
Application Filed
May 18, 2026
Non-Final Rejection mailed — §103
Aug 18, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103
Nov 05, 2026
Applicant Interview (Telephonic)
Nov 05, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780996
Solution Masterbatch With Resonant Acoustic Mixing
3y 10m to grant Granted Nov 03, 2026
Patent 12760142
COMPOSITION FOR FORMING RESIST UNDERLAYER FILM
4y 4m to grant Granted Oct 13, 2026
Patent 12735527
Low Density Flame Retardant Two-Component Composition for Structural Void Filling
4y 0m to grant Granted Sep 15, 2026
Patent 12698361
METHOD FOR PRODUCING POLYMER
4y 2m to grant Granted Aug 04, 2026
Patent 12692349
SUBSTRATE FOR HEAT-RESISTANT ELECTRONIC DEVICE
4y 10m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
75%
With Interview (+16.0%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 754 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month